| For: | Fallahzadeh MA, Asrani SK, Tapper EB, Saracino G, Rahimi RS. Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis. World J Clin Cases 2022; 10(23): 8097-8106 [PMID: 36159543 DOI: 10.12998/wjcc.v10.i23.8097] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v10/i23/8097.htm |
| Number | Citing Articles |
| 1 |
Mette M. Lauridsen, Jasmohan S. Bajaj. Inpatient management of hepatic encephalopathy. Clinical Liver Disease 2024; 23(1) doi: 10.1097/CLD.0000000000000105
|
| 2 |
Ting Wang, Deli Zou, Xingshun Qi. Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply. Alimentary Pharmacology & Therapeutics 2025; 61(1): 194 doi: 10.1111/apt.18371
|
| 3 |
Daisy K. Maclaine, Kosha J. Mehta. Principles of Non-selective Beta-blocker Usage for Cirrhosis-associated Complications. SN Comprehensive Clinical Medicine 2025; 7(1) doi: 10.1007/s42399-025-02071-3
|
| 4 |
Florent Broca, Mylène Dufrenoy, Mickaël Martin. Prise en charge de l’encéphalopathie hépatique : revue générale. La Revue de Médecine Interne 2025; 46(4): 211 doi: 10.1016/j.revmed.2024.10.007
|
| 5 |
A Bhateja, V Bodh, A Chauhan. Role of nutrition in the management of hepatic encephalopathy: Do we know all?. Journal of Gastroenterology and Hepatology 2023; 38(4): 664 doi: 10.1111/jgh.16131
|
